» Articles » PMID: 20161832

Phenotypic Fingerprinting of Small Molecule Cell Cycle Kinase Inhibitors for Drug Discovery

Overview
Publisher Bentham Open
Specialty Biochemistry
Date 2010 Feb 18
PMID 20161832
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Phenotypic drug discovery, primarily abandoned in the 1980's in favor of targeted approaches to drug development, is once again demonstrating its value when used in conjunction with new technologies. Phenotypic discovery has been brought back to the fore mainly due to recent advances in the field of high content imaging (HCI). HCI elucidates cellular responses using a combination of immunofluorescent assays and computer analysis which increase both the sensitivity and throughput of phenotypic assays. Although HCI data characterize cellular responses in individual cells, these data are usually analyzed as an aggregate of the treated population and are unable to discern differentially responsive subpopulations. A collection of 44 kinase inhibitors affecting cell cycle and apoptosis were characterized with a number of univariate, bivariate, and multivariate subpopulation analyses demonstrating that each level of complexity adds additional information about the treated populations and often distinguishes between compounds with seemingly similar mechanisms of action. Finally, these subpopulation data were used to characterize compounds as they relate in chemical space.

Citing Articles

How Physiologic Targets Can Be Distinguished from Drug-Binding Proteins.

Mensa-Wilmot K Mol Pharmacol. 2021; 100(1):1-6.

PMID: 33941662 PMC: 8256883. DOI: 10.1124/molpharm.120.000186.


The cytotoxic, apoptotic and oxidative effects of carbonic anhydrase IX inhibitor on colorectal cancer cells.

Tuluce Y, Ahmed B, Koyuncu I, Durgun M J Bioenerg Biomembr. 2018; 50(2):107-116.

PMID: 29520697 DOI: 10.1007/s10863-018-9749-9.


LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.

Vakana E, Pratt S, Blosser W, Dowless M, Simpson N, Yuan X Oncotarget. 2016; 8(6):9251-9266.

PMID: 27999210 PMC: 5354729. DOI: 10.18632/oncotarget.14002.


The marine-derived pachycladin diterpenoids as novel inhibitors of wild-type and mutant EGFR.

Mohyeldin M, Akl M, Siddique A, Hassan H, El Sayed K Biochem Pharmacol. 2016; 126:51-68.

PMID: 27940262 PMC: 5272797. DOI: 10.1016/j.bcp.2016.12.003.


Phenotypic screening in cancer drug discovery - past, present and future.

Moffat J, Rudolph J, Bailey D Nat Rev Drug Discov. 2014; 13(8):588-602.

PMID: 25033736 DOI: 10.1038/nrd4366.

References
1.
Inglefield J, Larson C, Gibson S, Lebrec H, Miller R . Apoptotic responses in squamous carcinoma and epithelial cells to small-molecule toll-like receptor agonists evaluated with automated cytometry. J Biomol Screen. 2006; 11(6):575-85. DOI: 10.1177/1087057106288051. View

2.
Li F, Tiede B, Massague J, Kang Y . Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res. 2006; 17(1):3-14. DOI: 10.1038/sj.cr.7310118. View

3.
Barabasz A, Foley B, Otto J, Scott A, Rice J . The use of high-content screening for the discovery and characterization of compounds that modulate mitotic index and cell cycle progression by differing mechanisms of action. Assay Drug Dev Technol. 2006; 4(2):153-63. DOI: 10.1089/adt.2006.4.153. View

4.
Gold R, Schmied M, Giegerich G, Breitschopf H, Hartung H, Toyka K . Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques. Lab Invest. 1994; 71(2):219-25. View

5.
Low J, Huang S, Blosser W, Dowless M, Burch J, Neubauer B . High-content imaging characterization of cell cycle therapeutics through in vitro and in vivo subpopulation analysis. Mol Cancer Ther. 2008; 7(8):2455-63. DOI: 10.1158/1535-7163.MCT-08-0328. View